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Editor: 
We read with interest the paper of Cata and colleagues concerning perioperative blood 
transfusions, inflammatory response, and immunosuppression. In this interesting 
review, the authors discuss the understanding of the mechanisms by which transfusion 
affects immune function and could affect cancer progression. The authors conclude 
that transfusion of allogenic blood causes substantial alterations to the anti-/pro-
inflammatory milieu in the recipient that seems to be proportional to the stored age of 
the blood products. It seems that biological factors included in these packed red blood 
cells that affect the innate immune function, rather than leucocytes or soluble fractions, 
may be responsible for tumour-promoting effects.  
Arginase has gained importance due to the fact that NO synthases are dependent on 
the availability of L-arginine in the extracelullar environment. L-arginine is metabolized 
by NO synthase (NOS) to produce nitric oxide (NO) or by arginase to produce urea and 
ornithine, which is a precursor of polyamines, which are important during cellular 
proliferation. Expression of NOSs and arginases could co-regulate each other. 
Depletion of L-arginine by macrophages has been postulated as one of the several 
mechanisms that causes a decrease in CD3-zeta chain expression in cancer. In a 
tumour microenvironment, macrophages deplete arginine via their high arginase 
activity and profoundly down-regulate the tumour-infiltrating T-cells. L-arginine 
deficiency caused by high arginase activity, both at the tumour site and in circulating 
blood, has been associated not only with sustained tumour growth via polyamine 
synthesis but also with tumour escape from immune response. Although arginase has 
a short half-life of only a few hours in human blood, it might act in early stages of 
immunosuppression. High levels of free arginase after blood transfusion could underlie 
many of the deleterious outcomes, including immunosuppression and infection-related 
processes associated with transfusion of blood stored for long periods. 
The proposed detrimental effects of prolonged blood storage have been attributed in 
part to haemolysis of packed erythrocytes stored for a prolonged period, which leads to 
an increased oxyhaemoglobin concentration and NO scavenging. Indeed, the 
haemoglobin level in the storage bag supernatant was found to be higher after 40 days 
of storage than after 3 days of storage, indicating increased haemolysis, and infusion of 
40-day packed erythrocytes was recently suggested to lead to increased NO 
production from endothelial NOS, as a compensatory mechanism for reduced NO 
bioavailability caused by plasma oxyhaemoglobin scavenging of NO. However, 
although leucoreduced units of packed red blood cells contain fewer than 5×10−6 white 
blood cells, it should be noted that neutrophils, which undergo spontaneous cell death, 
constitutively express large amounts of arginase and even small contamination of 
packed red cell bags by neutrophils might, therefore, produce significant levels of 
arginase activity, apart from that derived from the red cells themselves. Recently, we 
found raised levels of free arginase in blood stored for long periods, which could 
corroborate these arguments and have implications for patients in whom 
immunosuppression is a major challenge.  
Thus, we suggest that increased haemolysis might be an important aspect in blood 
transfusion, leading to elevated levels of arginase and NOS, and, thereby, to L-arginine 
depletion that could eventually affect immune function and cancer progression. 
 
 
 
